Urinary Protein Profiles May Help Subtype and Detect Early-Stage Feline Chronic Kidney Disease
Researchers have identified specific urine protein patterns that may allow veterinarians to subtype chronic kidney disease (CKD) in cats, offering a potential shift away from relying on late-stage clinical indicators.
A study published on October 14, 2026, in the Journal of Proteome Research analyzed the urinary proteome of 64 cats to differentiate between disease states that currently often go undetected until significant renal damage has occurred.
- MMP-7 has emerged as a promising early-stage biomarker, showing elevated levels in cats with early CKD compared to healthy controls.
- Proteomic profiling identified three distinct subgroups among cats with CKD, suggesting diverse underlying pathophysiological mechanisms rather than a uniform disease process.
- The study utilized mass spectrometry to identify over 2,000 proteins, providing a framework for more individualized diagnostic and therapeutic approaches.
Feline CKD is frequently diagnosed only after serum creatinine levels rise, a point at which the disease is often advanced and irreversible. Because this condition is common in aging feline populations, distinguishing between natural age-related decline and pathological dysfunction remains a major obstacle in clinical practice.
According to dvm360.com, the research team compared urine samples from 30 healthy cats with those from 34 cats diagnosed with various stages of CKD to better characterize the molecular signatures of the disease.
The study, conducted within the feline CKD research program at The Ohio State University College of Veterinary Medicine, identified the enzyme MMP-7 as a potential candidate for early detection. MMP-7, which functions by degrading extracellular matrix components, was the only protein in the study that correlated with serum creatinine levels across all 64 subjects.
While this protein showed promise, researchers said that early-stage disease remained difficult to distinguish from healthy profiles when analyzed in isolation, indicating that single-marker diagnostics may be insufficient for the heterogeneous nature of the disease.

“Chronic diseases are often heterogeneous, which makes them challenging to encapsulate with one protein,” Katelyn Brusach, lead researcher of the study, told technologynetworks.com. By grouping proteins based on their trends across disease states, the investigators successfully identified three distinct clusters that may correspond to different clinical phenotypes.
| Subgroup | Clinical Characteristics | Potential Pathophysiology |
|---|---|---|
| Group 1 | Stable stage 2-3 CKD | Indeterminate; potentially stable progression |
| Group 2 | Younger males, advanced disease | Immune-mediated glomerulonephritis |
| Group 3 | Elevated cell membrane proteins | Tubular epithelial dysfunction or injury |
The second subgroup identified in the study consisted of younger male cats with advanced proteinuric disease and an enrichment of proteins associated with immune response and complement activation. While the researchers suspected immune-mediated glomerulonephritis, they emphasized that such a diagnosis could not be confirmed without histopathological biopsy, which is often invasive and cost-prohibitive in clinical settings.
The third subgroup, characterized by elevated proteins related to cell membranes and signal receptors, likely represents classical late-stage feline CKD, where tubulointerstitial nephritis is the primary driver of morbidity.
The researchers acknowledged several limitations, including the small number of cats representing stage 1 and stage 4 disease, as well as a median age discrepancy between the healthy control group and the CKD cohort.
Future investigations will require larger, more diverse populations to validate these proteomic signatures. “By leveraging a deeply profiled urinary proteome, we were able to use protein profiles to measure disease differences that individual protein markers could miss,” Brusach said to phys.org.
The project was supported by funding from Zoetis Inc. and received additional grant support from the National Institutes of Health. As the field moves toward more personalized medicine, veterinarians are encouraged to discuss emerging diagnostic options with board-certified veterinary internists or specialists in nephrology and urology to ensure that the latest evidence-based protocols are applied to high-risk patients.
Moving forward, the integration of targeted assays into standard clinical practice may eventually allow for earlier intervention and more precise management of feline renal health.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.